Comparative GLP-1 and GIP Weight-Loss Evidence Quiz

Q1. In the reviewed evidence, which drug generally produced greater average weight loss?
- Semaglutide
- Tirzepatide
- Exenatide
- Liraglutide
Answer: Tirzepatide[[cite:1]][[cite:2]]
Q2. Which study-design issue most strongly limits confidence in the semaglutide versus tirzepatide comparison?
- The comparison came entirely from direct randomized head-to-head trials
- Heterogeneity prevented meta-analysis and direct head-to-head randomized trials were scarce
- Follow-up was always longer than 5 years
- Only one drug had any gastrointestinal adverse events
Answer: Heterogeneity prevented meta-analysis and direct head-to-head randomized trials were scarce[[cite:3]][[cite:4]]
Q3. Which adverse events were most commonly reported with these agents in the trials?
- Rash, arthralgia, and insomnia
- Nausea, vomiting, diarrhea, and constipation
- Hair loss and tinnitus
- Hypertension and bradycardia
Answer: Nausea, vomiting, diarrhea, and constipation[[cite:5]][[cite:6]]
Q4. What is the best evidence-based caveat about long-term follow-up in the reviewed literature?
- Most studies followed participants for several years, so durability is well established
- Treatment durations ranged from 16 to 104 weeks, with a median of 43 weeks in one review, and most studies were relatively short
- Long-term follow-up was unnecessary because outcomes were identical across studies
- No study reported any follow-up length
Answer: Treatment durations ranged from 16 to 104 weeks, with a median of 43 weeks in one review, and most studies were relatively short[[cite:7]][[cite:8]]
Q5. What does the evidence suggest about heterogeneity of treatment effects?
- There were no subgroup differences reported anywhere
- Subgroup data suggested possible differences, but one review said the data were insufficient for stratified analyses
- Only patients with diabetes were studied, so heterogeneity could not be assessed
- All studies found identical effects across every subgroup
Answer: Subgroup data suggested possible differences, but one review said the data were insufficient for stratified analyses[[cite:9]][[cite:10]]

nausea, vomiting, diarrhea, and constipation

insufficient to support stratified analyses

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials

Comparative GLP-1 and GIP Weight-Loss Evidence Quiz

Explore related topics